Disclosures experts
All participating experts have declared that the presentions provide a balanced view of therapeutic options and are entirely free of promotional bias.
Other potential relevant (financial) relationships or activities are disclosed below.
(Date of disclosures: april 2022)
Fredrik Schjesvold, MD, PhD
Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway
Disclosure
Board membership:AbbVie, Amgen, Celgene, Janssen, Novartis, and Oncopeptides AB
Research Grants: Celgene, GlaxoSmithKline, Janssen, Oncopeptides AB, and Sanofi
Shareholder: Nordic Nanovector, Oncopeptides
Honorarium:Amgen, Bristol Myers Squibb, Celgene, Janssen, Novartis, Oncopeptides AB, Schain, Skylite DX, Sanofi, and Takeda
Professor Xavier Leleu, MD, PhD
Department of Hematology, Academic Hospital of Poitiers, France
Disclosure
Consultancy: Janssen-Cilag, Celgene-Bristol Myers Squibb, Amgen, Takeda, Novartis, Merck, Gilead Sciences, Abbvie, Roche, Karyopharm Therapeutics, Oncopeptides, Carsgen Therapeutics, and GlaxoSmithKline
Honorarium: Janssen-Cilag, Celgene-Bristol Myers Squibb, Amgen, Novartis, Takeda, Sanofi, Abbvie, Merck, Roche, Karyopharm Therapeutics, Carsgen Therapeutics, Oncopeptides, and GlaxoSmithKline
Travel/accommodations/meeting expenses unrelated to activities listed: Takeda
Agoston Gyula Szabo, MD
Department of Hematology, Rigshospitalet Copenhagen, Denmark
Disclosure
Consultancy: Takeda, Sanofi, Janssen
Honorarium: Sanofi
Inger Nijhof, MD, PhD
Department of Internal Medicine, St. Antonius Hospital, The Netherlands
Disclosure
Board membership: Amgen, Janssen, Celgene-Bristol Myers Squibb
Honorarium: Amgen, Janssen, Celgene-Bristol Myers Squibb, Sanofi
Ville Varmavuo, MD PhD
Chief Medical Officer in Education, Internal Medicine, Kotka, Finland
Disclosure
Consultancy: Abbvie, Amgen, Celgene, Janssen-Cilag, Roche, Sanofi
Honorarium: Sanofi
Valdas Peceliunas, MD
Department of Hematology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
Disclosure
Honorarium: Sanofi
Clinical trials, principal investigator: Sanofi
Isabelle Vande Broek, MD, PhD
Department of Internal Medicine, St. Antonius Hospital, The Netherlands
Disclosure
Honorarium: Sanofi
Disclaimer: The purpose of this e-learning is to provide you as an HCP with relevant information on the basis of which you can draw your own conclusions. This information is not intended to provide recommendations regarding indications, dosages, or other statements not listed in the Summary of Product Characteristics of the products concerned or not listed in the local applicable guidelines for multiple myeloma.
